We assessed CD4 memory T cells by flow cytometry for cell surface markers and induction of cytokine expression. We found that 20/20 donors responded to the chimeric peptide TpD with a synthetic cathepsin S cleavage site. Individual peptides alone showed fewer numbers of cells responding in fewer numbers

of subjects. The frequency of responders to individual peptides (T and D, 10% selleck kinase inhibitor and 35% respectively) was lower than that reported by others, perhaps due to the use of a different assay [3], [4], [5], [6], [7], [8], [9], [10] and [11]. Interestingly the recall response to the chimeric peptide (TD) was greater than the sum of the response to the individual epitopes. Memory T cells can be characterized as effector or central memory cells by cell surface markers (CD4, CD45RA, CD45RO, CD27, CCR7) and cytokine expression (IFN-γ, TNF-α and IL-4) [27], [28] and [29]. Central memory

T cells are thought to give a faster and better response to epitope challenge than naïve T cells. Further characterization showed that the T cells responding to TpD had cell surface markers and cytokine expression consistent with central memory CD4 cells. Based on these results we selected TpD for nanoparticle vaccine formulation, and evaluation in mouse and primate animal models. We used a fully synthetic nanoparticle vaccine against nicotine, as a model system to test the activity of the TpD peptide. Studies in mice demonstrated that TpD was both necessary and sufficient for the ability to induce a robust anti-nicotine antibody response. Nanoparticles lacking TpD induced science little or no antibody production,

Pfizer Licensed Compound Library solubility dmso while TpD-containing nanoparticles induced antibody titers which increased with each successive boost. In particular, a boost administered at day 169, 141 days after the last immunization, induced a 19-fold increase in antibody titer, indicating that TpD induced long term memory T cells. This was confirmed by assessment of in vitro antigen-specific T cell recall to TpD using lymphocytes from immunized mice. Positive results achieved with the mouse studies prompted us to study more relevant nonhuman primate models, initially with a small cohort of 4 rhesus monkeys, and subsequently with a large cohort of 50 cynomolgus monkeys previously immunized with a DT and TT vaccine. Both studies were designed to provide an assessment of antibody and T cell help data over an extended period of time. Monkeys were from an outbred population, so their MHC class II alleles are variant and therefore a good model to test the ‘universality’ of TpD. Rhesus monkeys immunized with the nicotine nanoparticle produced sustained antibodies in a dose-dependent fashion, and T cell recall for over 4 months. The cynomolgus monkeys also showed a robust and dose dependent antibody response to a nicotine nanoparticle vaccine.